The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year ...

Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

With FDA Approval, MISTR Is Set to Deliver Nationwide Access to Lenacapavir Ushering in a New Era of HIV Prevention Two Shots ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® ...

WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...